EQR
53
-6
RSG
68
-6
EL
37
7
GOOGL
54
3
EQIX
73
-2
KMB
44
2
INTU
53
-3
WFC
75
-5
ROST
67
-4
ROK
62
6
PVH
70
6
FDX
37
-6
NAVI
55
-2
SJM
33
14
AA
56
-5
AMT
43
-2
CMA
58
-6
AIG
45
-5
MA
65
-2
LEG
47
4
EQR
53
-6
RSG
68
-6
EL
37
7
GOOGL
54
3
EQIX
73
-2
KMB
44
2
INTU
53
-3
WFC
75
-5
ROST
67
-4
ROK
62
6
PVH
70
6
FDX
37
-6
NAVI
55
-2
SJM
33
14
AA
56
-5
AMT
43
-2
CMA
58
-6
AIG
45
-5
MA
65
-2
LEG
47
4
Financhill
Back

Dianthus Therapeutics 10K Form

Sell
37

DNTH
Dianthus Therapeutics

Last Price:
25.31
Seasonality Move:
19.62%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DNTH News And Ratings

See the #1 stock for the next 7 days that we like better than DNTH

DNTH Financial Statistics

Sales & Book Value

Annual Sales: $2.83M
Cash Flow: $-21.29M
Price / Cash Flow: 0
Annual Sales: $11.51
Price / Book: 2.25

Profitability

EPS (TTM): -2.50290
Net Income (TTM): $-67.09M
Gross Margin: --
Return on Equity: -23.69%
Return on Assets: -22.7%

Dianthus Therapeutics Earnings Forecast

Key Dianthus Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,162.10% of Revenue.
  • The Net Earning history of DNTH is -1,541.22% of Total Revenues.
  • Per Share Earnings over the last 3 years have been positive in 0 years.

Dianthus Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: DNTH
Website: dianthustx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 18.3
Quick Ratio: 18.07

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

DNTH Technical Analysis vs Fundamental Analysis

Sell
37
Dianthus Therapeutics (DNTH) is a Sell

Is Dianthus Therapeutics a Buy or a Sell?